TY - JOUR
T1 - The Clinical Impact of Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Preserved Liver Function
AU - New FP Study Group
AU - Kurume Liver Cancer Study Group of Japan
AU - Iwamoto, Hideki
AU - Niizeki, Takashi
AU - Nagamatsu, Hiroaki
AU - Ueshima, Kazuomi
AU - Tani, Joji
AU - Kuzuya, Teiji
AU - Kasai, Kazuhiro
AU - Kooka, Youhei
AU - Hiraoka, Atsushi
AU - Sugimoto, Rie
AU - Yonezawa, Takehiro
AU - Tanaka, Satoshi
AU - Deguchi, Akihiro
AU - Shimose, Shigeo
AU - Shirono, Tomotake
AU - Sakai, Miwa
AU - Suzuki, Hiroyuki
AU - Moriyama, Etsuko
AU - Koga, Hironori
AU - Torimura, Takuji
AU - Kawaguchi, Takumi
N1 - Publisher Copyright:
© 2022 by the authors.
PY - 2022/10
Y1 - 2022/10
N2 - Background: Systemic treatments are recommended for advanced hepatocellular carcinoma (HCC) in preserved liver function. However, their effects are unsatisfactory in some tumor conditions, particularly macrovascular invasion (MVI) including major portal vein tumor thrombus (PVTT). We compared the efficacy of hepatic arterial infusion chemotherapy (HAIC) regimens New-FP and sorafenib for various tumor conditions in preserved liver function. Methods: We retrospectively collected the data of 1709 patients with HCC who were treated with New-FP or sorafenib. Survival was assessed after propensity score matching. Subgroup analyses were conducted: cohort 1 (no MVI or extrahepatic spread (EHS)), cohort 2 (MVI only), cohort 3 (EHS only), cohort 4 (MVI and EHS), and cohort 5 (major PVTT). Results: The New-FP group had a longer median survival time (MST) than the sorafenib in the whole analysis (18 vs. 9 months; p < 0.0001). New-FP demonstrated a longer MST compared with sorafenib in cohort 2 and cohort 4. In cohort 5, the MST of the New-FP group was 16 months, while that of sorafenib was 6 months (p < 0.0001). For major PVTT-HCC, the response rate of New-FP was 73.0%. The MST of patients who achieved complete response with New-FP was 59 months. Conclusions: HAIC using New-FP is promising for patients with MVI- and major PVTT-HCC in preserved liver function.
AB - Background: Systemic treatments are recommended for advanced hepatocellular carcinoma (HCC) in preserved liver function. However, their effects are unsatisfactory in some tumor conditions, particularly macrovascular invasion (MVI) including major portal vein tumor thrombus (PVTT). We compared the efficacy of hepatic arterial infusion chemotherapy (HAIC) regimens New-FP and sorafenib for various tumor conditions in preserved liver function. Methods: We retrospectively collected the data of 1709 patients with HCC who were treated with New-FP or sorafenib. Survival was assessed after propensity score matching. Subgroup analyses were conducted: cohort 1 (no MVI or extrahepatic spread (EHS)), cohort 2 (MVI only), cohort 3 (EHS only), cohort 4 (MVI and EHS), and cohort 5 (major PVTT). Results: The New-FP group had a longer median survival time (MST) than the sorafenib in the whole analysis (18 vs. 9 months; p < 0.0001). New-FP demonstrated a longer MST compared with sorafenib in cohort 2 and cohort 4. In cohort 5, the MST of the New-FP group was 16 months, while that of sorafenib was 6 months (p < 0.0001). For major PVTT-HCC, the response rate of New-FP was 73.0%. The MST of patients who achieved complete response with New-FP was 59 months. Conclusions: HAIC using New-FP is promising for patients with MVI- and major PVTT-HCC in preserved liver function.
KW - hepatic arterial infusion chemotherapy
KW - propensity score matching
KW - retrospective cohort study
KW - sorafenib
KW - systemic treatment
UR - http://www.scopus.com/inward/record.url?scp=85139852087&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139852087&partnerID=8YFLogxK
U2 - 10.3390/cancers14194873
DO - 10.3390/cancers14194873
M3 - Article
AN - SCOPUS:85139852087
SN - 2072-6694
VL - 14
JO - Cancers
JF - Cancers
IS - 19
M1 - 4873
ER -